Jason Amello

Jason Amello discloses dealings in 4 companies, chiefly Akebia Therapeutics, Inc., Genzyme Corp and Candel Therapeutics, Inc. Over a trading history stretching from 24 May 2010 to 28 November 2023, the count stands at 26 filings.

On the open market, the record shows 4 purchases worth €69k and 3 sales worth €443k. Netting one side against the other leaves €374k of net selling. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 11 share grants and 5 option exercises.

Half of the purchases are above €7,788 and half below.

The newest entry dates from 30 November 2023: a share grant of €17k, in Candel Therapeutics, Inc. The clock since the last published purchase (12 December 2022) now reads 1,411 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.